FDA panel votes in favor of approval for Sanofi‘s Multaq – A panel of cardiology experts recommended Wednesday that an experimental drug from Sanofi-Aventis be approved to treat irregular heart rhythms linked to stroke. The Food and Drug Administration’s cardiology drug panel voted 10-3 in favor of the drug Multaq. The pill is designed to treat atrial fibrillation, a condition that interferes with the contractions of the heart’s upper chambers.
Pfizer may have to sell off some Animal Health assets in order to complete Wyeth transaction.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff